(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 113.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.64%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.92%.
Cytokinetics's revenue in 2026 is $87,211,000.On average, 21 Wall Street analysts forecast CYTK's revenue for 2026 to be $14,803,837,603, with the lowest CYTK revenue forecast at $6,482,242,006, and the highest CYTK revenue forecast at $29,726,272,188. On average, 19 Wall Street analysts forecast CYTK's revenue for 2027 to be $46,603,722,987, with the lowest CYTK revenue forecast at $36,389,710,818, and the highest CYTK revenue forecast at $61,820,816,050.
In 2028, CYTK is forecast to generate $111,888,304,476 in revenue, with the lowest revenue forecast at $72,405,290,954 and the highest revenue forecast at $182,419,274,068.